Date: 2014-06-23
Type of information: Financing round
Company: Dimension Therapeutics (USA - MA)
Investors: OrbiMed (USA - NY) Fidelity Biosciences (USA - MA)
Amount: $30 million
Funding type: financing round
Planned used: Dimension Therapeutics is a gene therapy company focused on developing novel therapies to treat rare diseases. Launched by Fidelity Biosciences in 2013, the Dimension team comprises biotech industry veterans and renowned thought leaders in gene therapy and rare diseases. The company is focused on building its adeno-associated virus (AAV) therapeutic capabilities and advancing multiple gene therapy programs in rare diseases through partnerships with REGENX Biosciences and the University of Pennsylvania, which provide Dimension with exclusive gene therapy intellectual property and preferred access to multiple best-in-class AAV vectors based on REGENX’s NAV® technology.
Others: * On June 23, 2014, Dimension Therapeutics, a gene therapy company focused on developing novel treatments for rare diseases, announced the closing of a $30 million financing. New investor OrbiMed joined existing investor Fidelity Biosciences in the round.
Therapeutic area: Rare diseases
